Pfizer's Bourla Urges Patience As COVID-19 Vaccine Data Timeline Lags

Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.

Hourglass with sun light background
Investors and the public will need to keep waiting for COVID-19 vaccine data • Source: Shutterstock

Pfizer Inc. set an expectation that it would have the first Phase III efficacy data on its COVID-19 vaccine candidate in October, but that may now be unlikely. The company said on 27 October that the trial's data safety monitoring committee remains blinded to the data and that no analysis has been conducted. The update came with Pfizer's third quarter financial disclosures – when many investors and observers expected the efficacy data might be released.

CEO Albert Bourla said the company would update the public on the results of a conclusive positive or negative data...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip